Risk Factors Update Summary
- Addition of the Signatera test to revenue sources, impacting overall billing operations significantly.
- Increase in accumulated deficit from $1.2 billion to $1.9 billion, indicating continued losses.
- Potential impact of FDA regulations on LDTs, requiring adherence to additional regulatory requirements.
- Launch of over 15 product offerings since 2009, with test volumes growing significantly.
- Increase in total addressable market opportunity and forecasts, potentially affecting growth rates.
- Changes in reimbursement environment for molecular diagnostics, affecting financial and operating results.
- Expansion into new markets and industries with product enhancements, indicating increased diversification.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1604821&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.